|  |
| --- |
| **Baseline Characteristics and Oral Corticosteroid Reduction in Severe Asthma** |
| Jana Moody1\*, Joy Lee2,3\*, Christian Domingo4, Nicola A Hanania5, G Walter Canonica6, David MG Halpin7, Njira L Lugogo8, Chin Kook Rhee9, Scott Nash10, Nami Pandit-Abid11 |
| *1Sanofi, New South Wales, Australia 2Allergy, Asthma and Clinical Immunology and Respiratory medicine, Alfred Health, Melbourne, Victoria, Australia 3School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia 4Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Universitat Autònoma de Barcelona, Barcelona, Spain 5Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA 6Humanitas University and Research Hospital-IRCCS, Milan, Italy 7University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK 8University of Michigan, Ann Arbor, MI, USA 9College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea 10Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA 11Sanofi, Bridgewater, NJ, USA* |
| **Introduction/Aim:** We assessed the association between baseline disease characteristics and OCS elimination in patients with OCS-dependent severe asthma (VENTURE; NCT02528214).  **Methods:** Patients received dupilumab 300mg q2w or placebo for 24 weeks (w); those who eliminated OCS at W24 were stratified by baseline pre-bronchodilator (BD) percent predicted (pp) FEV1 </≥60% or post-BD FEV1 ≤/>median (1.78L) and odds ratios (OR) were calculated for achieving OCS elimination (W24).  **Results:** In patients with baseline pre-BD ppFEV1 <60%/≥60%, OR for dupilumab vs placebo were 6.8/1.3 (*Pint*=0.03). In patients with baseline post-BD FEV1 ≤median/>median, OR were 6.1/1.8 (*Pint*=0.08). In those with pre-BD ppFEV1 ≥60% or post-BD FEV1 >median, more placebo patients achieved OCS elimination.  **Conclusion:** Dupilumab versus placebo showed strong statistically significant association with achieving OCS elimination at W24 in patients with OCS-dependent severe asthma and pre-BD ppFEV1 <60% or post-BD FEV1 ≤median at baseline. Moderate associations (non-significant) were observed in patients with baseline pre-BD ppFEV1 ≥60% or post-BD FEV1 above median at baseline.  **Grant Support:** \*Presenting on behalf of authors. Data first presented at the American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting; Anaheim, CA, USA; November 9-13, 2023. Research sponsored by Sanofi and Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT02528214. Medical writing/editorial assistance was provided by Orthis Saha, PhD of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the [Good](https://www.acpjournals.org/doi/10.7326/M15-0288) [Publication Practice guideline.](https://www.acpjournals.org/doi/10.7326/M15-0288)  **Key words:** Asthma, oral corticosteroids, baseline characteristics, dupilumab |

**Disclosures: J Lee:** has received speaker fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca and Sanofi**. C Domingo:** reports acting as consultant for GSK, AstraZeneca, Novartis and Sanofi and has received funding for travel or speaker fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, Novartis, Stallergenes, MSD and Pfizer. **NA Hanania:** reports receiving personal fees from AstraZeneca, Genentech, Sanofi Genzyme, GSK, Mylan, Novartis, and Regeneron for serving as an advisor or consultant; he also received research support from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi Genzyme, Genentech, and GSK. **GW Canonica:** has previously received grant or research support from Boehringer Ingelheim, ALK-Abelló, and Stallergenes and honoraria or consultation fees from Menarini, GlaxoSmithKline, Sanofi, Teva, Hal, AstraZeneca, and Novartis. **DMG Halpin:** reports personal fees from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Chiesi and GlaxoSmithKline, personal fees and non-financial support from Novartis, and personal fees from Pfizer and Sanofi.**NL Lugogo:** received consulting and advisory board fees from Amgen, AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speakers’ bureau presentations from AstraZeneca and GlaxoSmithKline; travel support from AstraZeneca; and her institution received research support from Amgen, AstraZeneca, Avillion, Gossamer Bio, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva. **CK Rhee:** reports personal fees from MSD, AstraZeneca, GSK Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi and Bayer, outside the submitted work. **S Nash:** Regeneron Pharmaceuticals, Inc. — employee and shareholder. **Moody J**, **N Pandit-Abid:** Sanofi — employee, may hold stock and/or stock options in the company.